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Abstract
Migraine is a common neurological disease that affects both women and men in a dif-
ferent age. It is believed that migraine is a multifactorial disease with strong genetic and 
environmental factors. Current molecular studies in migraine are focused on biochemical 
(homocysteine, asymmetric dimethylarginine) and genetic (ACE, MTHFR, MTR, MTRR, 
CBS, eNOS, NOTCH3) risk factors associated with vascular diseases. Polymorphisms and 
mutations in mentioned genes predispose to migraine as well as cardiovascular diseases 
and stroke. According to the literature data, 13–15% of migraine with aura patients suffer 
from vascular diseases, too. The strict relation between migraine with aura and stroke 
is observed in cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy. Lifestyle plays an important role both in the pathomechanism of 
migraine and vascular diseases. Hypertension, obesity, dyslipidemia, and diabetes mel-
litus are the important risk factors for those pathological conditions. Therefore, early 
diagnosis of migraine and the implementing effective pharmacotherapy can lead to the 
prevention of cardiovascular and cerebrovascular diseases.
Keywords: genetic variants, CADASIL, risk factors, cardiovascular diseases, stroke, 
migraine
1. Introduction
Migraine is a primary headache disorder and one of the most common neurological diseases 
because it affects 11% of the adult population worldwide. Due to clinical manifestation, the 
disease is divided into two main subtypes: migraine with aura (MA), the classic form, and 
migraine without aura (MO), the common form [1]. The exact pathomechanism of migraine 
remains unclear, but the new explanation underlines the neurovascular background with an 
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important role of trigeminovascular system and cortical spreading depression (CSD). CSD 
is a wave of electrophysiological hyperactivity followed by depression spreading across the 
cortex. This process leads to decrease in blood flow and is manifested in the aura. Migraine is 
a polygenetic disease with the contribution of environmental factors [2].
The most significant risk factor of migraine is gender, as migraine is more prevalent in females 
than in males, but a female: male ratio ranging from 2:1 to 4:1 in several populations [3, 4]. The 
ratio is not consistent across the age because there is no difference in the percentage of boys 
and girls among children aged 7–9 affected by migraine. After that age, the migraine is more 
common in females. The prevalence of migraine is the highest in girls after puberty and among 
women aged 30–50, and declines in post-menopausal period. However, the similar trend in 
prevalence of migraine is observed in adult men, but the absolute values are lower (Figure 1) [5].
Moreover, female patients with migraine are more prone to vascular diseases as compare 
to males. The correlation between migraine and vascular diseases, especially cerebrovascu-
lar, has been studied from ages due to similar features, such as neurovascular component, 
a decrease in blood flow and platelet aggregation. MA is often associated with stroke symp-
toms and ischemic, or rarely hemorrhagic stroke events. No such strong relation was found in 
MO or other headaches [6, 7]. Numerous meta-analyses underline that MA doubles the risk 
of ischemic stroke [8–10]. This association is stronger in younger adults, especially women 
<45 years of age. In the young woman with MA, the combination of smoking and oral contra-
ceptive use has a prominent role in stroke developing [8, 9]. The high frequency of migraine 
attacks and longstanding history of migraine are also the risk factors for stroke [6, 11]. It may 
be explained by subclinical ischemic brain lesions observed in magnetic resonance imaging 
(MRI) of those patients [6].
The risk of ischemic stroke in migraine patients may also be increased by cardiovascular risk 
factors, e.g., diabetes, hypertension, obesity and dyslipidemia [12], hyperhomocysteinemia, 
as well as genetic factors, e.g., C677T polymorphism in MTHFR, insertion/deletion polymor-
phism in ACE or mutations in NOTCH3 [13].
Figure 1. Migraine prevalence by age and sex, based on [5].
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2. Cardiovascular risk factors
The cardiovascular diseases (CVD) and MA often coexist. The CSD involved in MA patho-
physiology, migraine attacks frequency, prothrombotic effects, and impaired vascular reactiv-
ity in migraine patients or even migraine-specific treatments may increase the risk of CVD [14]. 
The risk factors for vascular diseases include changes in female sex hormones, hypertension, 
obesity, dyslipidemia and diabetes mellitus or elevated concentration of homocysteine (Hcy) 
and asymmetric dimethylarginine (ADMA).
2.1. Sex hormones
Gender differences in migraine prevalence can be explained by the influence of female 
hormones. Fluctuation in female sex hormones levels correlates with migraine, as attacks 
frequency is higher during menstruation [15, 16]. The peak estradiol level in women with men-
strual related migraine is lower than in healthy group [17]. Another sex hormone, estrogen is 
also indirectly involved in pain transmission and pathophysiology of migraine. Additionally, 
estrogen, which is involved in thrombotic propensity and vasodilatory response, play the pro-
tective role against CVD risk. The CVD prevalence surges during menopause, when hormone 
balance is changed. This relation can explain the higher risk of CVD among younger women 
suffering from migraine [16].
The prospective cohort study of Kurth et al. [18] shows a consistent link between migraine 
and CVD events and cardiovascular mortality in women with more than 20 years of follow-
up. The authors found that an approximately 50% increased risk of major CVD like myocar-
dial infarction, stroke, coronary artery procedures, and angina pectoris. The previous study 
in women indicates that only MA is associated with elevated risk of CVD [14, 19]. However, 
in the men group, migraine is correlated with increased risk of subsequent major CVD, which 
was driven by the increased risk of myocardial infarction [20].
2.2. Hypertension
The major CVD risk is hypertension, which high appearance was found in individuals with 
migraine [21]. Hypertension occurs in migraine patients, both females and males, in younger 
age than in the non-migraine population. The 5-year prospective cohort study in Finland 
demonstrated that migraine is associated with an increased risk of hypertension among 
working-age population [22]. Among patients suffered from hypertension-migraine comor-
bidity the onset of both disorders occur at about 45 years of age, with the migraine starting 
significantly later than in only migraine patients and hypertension significantly earlier than 
in the hypertension-only group. Moreover, comorbidity group has a higher occurrence of the 
history of cerebrovascular events [23]. It is important to control hypertension in migraine and 
apply the proper treatment, because uncontrolled may lead to worsening of a headache and 
therapeutic failure. It is also crucial for the control of cerebrovascular risk, which is already 
increased in patients with MA [24].
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2.3. Obesity
Modifiable risk factor for both CVD and migraine is obesity. Migraine and obesity are associated 
in several ways [25]. Obesity is related to higher migraine prevalence, higher attacks frequency, 
and also with elevated risk for developing chronic daily headache with migrainous features or 
transformation from an episodic migraine to chronic form [26, 27]. According to Bigal et al. [28], 
only 4.4% of migraneous with normal weight had 10–15 headache days per month, but percent-
age increases with bigger weight, in the overweight group it was 5.8%, in the obese 13.6%, and 
the morbidly obese 20.7%. The age and sex are also important covariates in associations between 
obesity and migraine [25].
The literature indicates that MA and obesity seem to be connected with CVD. It is known 
that such inflammatory mediators, like cytokines (interleukin 6—IL-6 and tumor necrosis 
factor-α—TNF-α), and calcitonin gene-related peptide (CGRP), which levels are increased 
in obese individuals, play important role in migraine pathophysiology. They may enlarge 
the number and duration of migraine attacks, which in turn cause central sensitization. 
Repeated central sensitization may be associated with neuronal damage and with poor 
modulation to pain. Plasma CGRP level is mostly elevated in women and its secretion 
can be increased by fat intake. Other peptides, the hypocretins (hypocretin-1 and -2) may 
also link the metabolism and pain. They control nociception and release of CGRP from 
trigeminal neurons. Hypocretins regulates appetite and energy metabolism: their activity 
is decreased in obesity. It is postulated that the dysmodulation in the hypocretinergic path-
ways is associated with increased susceptibility to neurogenic inflammation and migraine 
attacks [27, 28].
2.4. Dyslipidemia
Obesity is directly connected with dyslipidemia. Several studies explored the relationship 
between dyslipidemia and migraine in a cardiovascular context. The population-based 
study of men and women aged 20–65 year in the Netherlands s found that adult MA patients 
have “riskier” profile for CVD than MO [29]. The authors indicated that increased total 
cholesterol (≥240 mg/dL) and the total cholesterol to high-density lipoprotein cholesterol 
(HDL-C) ratio (>5) had been associated with MA. The study of Gruber et al. [30] showed 
that in normal weight MA patients, not only total cholesterol level is elevated, but also low 
density lipoprotein cholesterol (LDL-C) and oxidized LDL-C levels as compared to normal 
weight controls. It was demonstrated that elevated oxidized LDL-C increases the risk of 
migraine almost eight times. In the cross-sectional study from France, elevated levels of 
total cholesterol and triglycerides were associated with MA, but not with other headaches in 
the elderly [31]. There is also a correlation between cholesterol levels (total and LDL-C) and 
degree of migraine severity, with higher cholesterol values for more frequent and intense 
migraine attacks [32]. Moreover, the positive associations among MO, and VLDL cholesterol 
(VLDL-C) and remnant VLDL particles (VLDL3) were observed in women and men, respec-
tively. VLDL is fractioned into IDL and VLDL3, which has been previously connected with 
higher CVD risk [33].
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2.5. Diabetes mellitus
It is postulated that diabetes mellitus (DM) is associated with migraine, but there are conflicting 
results that relationship is interesting because DM affects vascular reactivity, induces neuropa-
thy, and can be important in the pathophysiology of migraine [34]. The prospective cohort study 
from Finland observed that women with a headache are more often diabetic [35]. Haghighi 
et al. [36] showed no significant differences in the prevalence of migraine between diabetic and 
non-diabetic patients, these results confirmed previous study [37]. However, the authors indi-
cated that migraine prevalence is related to the family history of migraine in the first-degree 
relatives, the history of hypoglycemia and durations of DM type 2. Other results demonstrated 
that migraine is significantly less prevalent in patients with DM than without DM [34, 38]. The 
study of Aamondt et al. [34] also showed that migraine prevalence is lower among patients with 
duration of DM ≥ 13 years or HbA1c levels >6.6%.
2.6. Hcy and ADMA
Hcy is an endogenous sulfur amino acid, which is formed as the intermediate product during 
metabolism of methionine in kidney, liver, small intestine, pancreas, blood vessels, and skin [39]. 
In its transformation, some enzymes and co-factors are involved, e.g., methylenetetrahydrofolate 
reductase (MTHFR), cystathionine beta synthase (CBS), methionine synthase (MS), also known 
as 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), folic acid, and vitamins B6 
and B12 [40]. Increased level of Hcy (which can lead to hyperhomocysteinemia) is an important 
risk factor for ischemic heart disease, venous thromboembolism, ischemic stroke, and other CVD 
[41]. The elevated Hcy level has also been reported in patients suffering from MA [42], which 
may indicate an increased risk of CVD in this group. Mechanisms of adverse effects of Hcy on 
blood vessels are seen in the intensification of oxidative stress, reduced amount of nitric oxide 
(NO), the cytotoxic effect on endothelial cells, inflammation in the vascular walls, and abnor-
malities of the coagulation process [43]. The level of Hcy may be regulated by polymorphisms in 
genes encoding enzymes necessary for its metabolism, e.g., MTHFR, MTR.
ADMA is a naturally occurring amino acid, an analog of L-arginine that competitively inhib-
its endothelial nitric oxide synthase (eNOS) activity, causing vasoconstriction and endothe-
lial dysfunction leading to CVD [44]. eNOS catalyzes arginine oxidation to NO, which is one 
of the strongest vasodilators in the human body. Studies have confirmed that NO, changing 
cerebral blood flow, is responsible for migraine headaches [45]. Elevated levels of ADMA 
have been reported in patients with migraine compared to the control group, without any dif-
ference between MA and MO. It is interesting that the same studies also showed higher NO 
level in migraineurs than in control. The possible reason for increase in both ADMA and NO 
concentrations may be an attempt to compensate for elevated NO level and excessive vasodi-
latation [46]. However, there are also reports that ADMA and NO levels in migraine patients 
do not differ from the control group [47]. Higher concentration of ADMA may be caused 
by abnormalities in the function of dimethylarginine dimethylaminohydrolase (DDAH) 
whose role is to degrade ADMA to dimethylamine and citruline [48]. There are two forms 
of this enzyme: DDAH1 and DDAH2, encoded by different genes: DDAH1 and DDAH2, 
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respectively. It was found that polymorphisms (rs233109, rs6669293, and rs12140935) in the 
DDAH1 gene may influence the ADMA level [49]. The interaction among Hcy, DDAH, and 
ADMA was also investigated. Studies conducted on neuronal cell cultures show that DDAH 
inhibition by Hcy results in higher ADMA accumulation and a decrease in NO production 
[50]. Overexpression of DDAH protects from adverse effects for cerebral blood vessels, that 
results from elevated levels of Hcy [51].
3. Genetic risk factors
Migraine is a polygenetic disease. According to population-based family studies, MA is 
four-times more common in individuals with first-degree relatives suffering from MA, while 
the risk for MO increases two-times in terms of having first-degree relatives with MO [52]. 
Therefore, numerous studies investigated the association between genetic polymorphisms or 
mutations and MA, MO. Polymorphisms in gene coding angiotensin I—converting enzyme 
(ACE) and in genes related to Hcy metabolism, may increase risk both for migraine and vas-
cular diseases. Moreover, the strict relation between migraine, especially MA and stroke, is 
presented in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL).
3.1. Angiotensin I-converting enzyme (ACE)
ACE, which is a part of the renin-angiotensin system (RAS), converts the inactive angiotensin 
I to angiotensin II. Angiotensin II is an active peptide responsible for vasoconstriction, regula-
tion of blood pressure and blood volume [53]. The ACE inhibitors are used in migraine pro-
phylaxis, and for hypertension and coronary artery disease treatment [54]. The activity of ACE 
may be controlled by insertion/deletion (I/D) polymorphism (rs1799752) in the ACE gene. The 
DD genotype of ACE I/D polymorphism is associated with the higher ACE activity, which 
increases angiotensin II level and in result leads to the imbalance in RAS [55]. The I/D poly-
morphism was linked to numerous diseases, e.g., hypertension, ischemic stroke, and migraine 
(MA, MO or an overall migraine, depending on the study) [56]. Thus, there is a possible asso-
ciation between this polymorphism, migraine, and CVD. According to Schurks et al. [57], the 
MA patients carrying D allele have the two-fold increased risk of CVD. The data about DD 
genotype and migraine attack frequency are inconsistent. Schürks et al. [58] showed that ACE 
D allele does not influence the MA or MO attack frequency while Paterna et al. [56] found that 
carrying the D allele determines more frequent MO attacks. The protective effect of II genotype 
may contribute to the reduction of the dose of ACE inhibitors in migraine prophylaxis [59].
Both polymorphisms in MTHFR and ACE genes promote oxidative stress, endothelial dys-
function and in consequence, may predispose to stroke. It was suggested that MTHFR C667T 
TT and ACE DD genotypes in combination might increase the migraine susceptibility, espe-
cially MA [60]; while the other study did not confirm this conclusion [61]. The meta-analysis 
indicated that MTHFR C667T TT genotype increases the MA risk, while the ACE II genotype 
protects against both MA and MO, but only in non-Caucasian populations [62].
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3.2. MTHFR, MTR, MTRR, CBS, and eNOS
MTHFR is responsible for the conversion of 5,10-methylenetetrahydrofolate (CH2THF) to 
5-methyltetrahydrofolate (CH3THF), which is a donor of the methyl group in remethylation of 
Hcy to methionine. Polymorphisms in MTHFR gene may be the reason of higher level of Hcy 
in blood. Fourteen rare mutations of MTHFR gene and one common C677T polymorphism in 
MTHFR gene were associated with severe enzymatic deficiency [63]. The MTHFR C677T poly-
morphism (Ala222Val) is associated with the decreased enzymatic activity to 30% in TT homo-
zygous subject and 60% in individuals with CT genotype as compared to wild type genotype 
CC [64]. Several studies analyzed the association between MTHFR gene polymorphisms and 
migraine and obtained different results. Studies carried out in Japanese and Turkish popula-
tion showed the higher frequency of TT genotype in migraine patients than in the controls [65, 
66]. Moreover, Kowa et al. [65] found the particularly high frequency of MTHFR C677T TT 
genotype in MA, what correlates with results of Caucasian population studies [67, 68] report-
ing that TT genotype may be a risk factor for MA, but not for MO. On the other hand, studies 
conducted on the group of Finns excluded the association between MTHFR C667T polymor-
phism and migraine [69]. Recent meta-analyzes confirmed that the TT genotype of MTHFR 
C677T polymorphism is significantly associated with the risk of MA both in Caucasian [70] 
and non-Caucasian group [71] and total migraine in the non-Caucasian group [70, 71].
Another, less common MTHFR gene polymorphism that may be associated with migraine 
is A1298C (Glu429Ala). Studies by Kara et al. [66] showed that CC genotype is more com-
mon in migraine patients than in control subjects. The MTHFR A1296C polymorphism also 
reduces the activity of MTHFR without the increase in Hcy level and decrease in folate level 
in individuals with CC genotype. However, heterozygous patients with both MTHFR C677T 
and A1298C polymorphisms had higher levels of Hcy as compared to those who carried only 
C677T MTHFR polymorphism [72, 73].
The level of Hcy and folate may also be altered by the polymorphism in MTR gene encoding 
MTR enzyme responsible for remethylation of Hcy to methionine with the participation of 
vitamin B12 and 5-methyltetrahydrofolate [74]. So far, one common polymorphism A2756G 
(Asp919Gly), has been described in the MTR gene [75]. However, the effect of this polymor-
phism on Hcy and folate levels is not entirely clear. Li et al. [76] showed an association of MTR 
A2756G with increased Hcy and decreased folate level. On the other hand, Klerk et al. [77] 
denied that G allele of MTR A2756G affects Hcy level. Also, there was no association between 
MTR A2756G and migraine [42, 78], even in the coexistence of MTHFR 677CT TT genotype [79].
Another enzyme involved in Hcy metabolism is 5-methyltetrahydrofolate-homocysteine meth-
yltransferase reductase (MTRR), encoded by MTRR gene. The MTRR A66G (Ile22Met) polymor-
phism may lead to elevated Hcy level [80, 81], with greater effects observed in individuals with 
GG genotype than GA [80]. Furthermore, the coexistence of MTRR A66G AG or GG genotypes 
with the MTHFR A677T TT genotype increases the adverse effect of the MTHFR variant [82].
MTHFD1 is a trifunctional enzyme composed of methylenetetrahydrofolate dehydrogenase, 
methyltetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetase, encoded by 
MTHFD1 gene. The most commonly analyzed polymorphisms of the MTHFD gene are G1958A 
Migraine and Risk Factors of Vascular Diseases
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(R653Q) and C401T (R134K). The G1958A or C401T polymorphism individually does not increase 
the risk of migraine [79, 83]. However, the risk of migraine, especially MO, increases when the A 
allele of MTHFD G1958A polymorphism occurs together with the T allele of MTHFR C677T poly-
morphism. On the other hand, the group of Australian scientists found no association of MTHFD 
C401T and G1958A with the increased risk of suffering migraine [79].
CBS is an enzyme responsible for the conversion of Hcy to cystathionine, a cysteine precursor, 
and is encoded by CBS gene. Numerous genetic variants in this gene have been described, 
including silent polymorphisms (C699T, C1080T) [84], sense change mutations (T833C, G919A) 
and insertions (844ins68) [85, 86]. The most common polymorphism of the CBS gene, the 
T833C, results in the elevated level of Hcy [87] and predisposes to stroke [88]. The 844ins68 
polymorphism alone does not affect Hcy plasma levels [89], whereas T833C/844ins68 induces 
mild hyperhomocysteinemia [90]. The occurrence of this insertion together with T allele of 
MTHFR C677T polymorphism results in lower Hcy levels as compared to the subject carrying 
only insertion [91]. The silent polymorphism in CBS gene seems to have a protective effect 
against CVD. Subjects with C699T TT genotype had lower Hcy level than subjects with the 
CC genotype [92] and consequently lower risk of CVD [93]. Also, CBS C1080T polymorphism 
leads to decrease in Hcy level, but this effect is endured by of 844ins68 mutation carriers [92]. 
On the other hand, the study conducted by Lievers et al. [94] showed no association between 
the occurrence of the silent polymorphisms and the change in plasma Hcy levels [94].
eNOS gene encoded endothelial NO synthase. Several polymorphisms in the eNOS gene 
were described, including T786C and G894T (Glu298Asp), but their relevance to migraine 
pathomechanism remains ambiguous. According to Eröz et al. [95], presentence of T alleles of 
eNOS T786C and eNOS G894T polymorphisms are more common in migraine patients than in 
controls. Other studies indicated that the TT genotype of eNOS G894T is associated only with 
a higher risk of MA [96] or there is no association [97].
3.3. CADASIL
The strict relation between MA and stroke was observed in CADASIL syndrome. It belongs to 
the group of leukodystrophies and is caused by mutations in NOTCH3 gene [98].
CADASIL is the most frequent inherited ischemic disease of a small vessel of the brain [98]. The 
key features of CADASIL are MA, recurrent subcortical ischemic events and vascular demen-
tia. The subcortical ischemic stroke is presented in 85% CADASIL patients in mean age 46 
without atherosclerosis risk factors. Two of three cases are the lacunar stroke, while one of 
three is ishemispheric stroke. 20–40% of individuals suffer from psychiatric disorders, mostly 
depression or apathy. Dementia is presented in 31–60% of CADASIL patients, aged between 50 
and 60, as a result of stroke history, leading to severe disability and premature death [99, 100].
Often (20–40% of cases) the inaugural symptom of CADASIL is MA started in the second–third 
decade of life (females: 25; males: 30–35 year of life). Interestingly, MA is five-times more fre-
quent in CADASIL patients than in general population and may remain as the isolated symp-
tom [100]. CADASIL patients may experience aura without a headache or atypical aura (e.g., 
hemiplegic, basilar, or prolonged) or even acute confusional migraine. Thus it is suggested that 
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atypical aura should indicate the diagnosis of CADASIL [101–104]. The frequency of MA attacks 
decreases after the disease progression (stroke event). Unfortunately, migraine as a common 
neurological disease is not a specific symptom of CADASIL, which often is misdiagnosed [100].
As mentioned before, CADASIL is a result of the mutation in the NOTCH3 gene (19p13.12), 
encoding receptor protein NOTCH3. NOTCH receptors are made up of the functional 
extracellular domain (ECD)—containing multiple epidermal growth factor-like (EGF-like) 
repeats, the transmembrane domain and intracellular domain (ICD). The variants of NOTCH 
(NOTCH1–4) differ in the number of EGF repeats [105]. The NOTCH3 is essential for the 
development of vascular smooth muscle cells (VSMC) and maintenance of their function. 
Moreover, it protects against apoptosis and regulates the response of smooth muscle cells to 
external factors. NOTCH3 occurs mostly in the arteries and capillaries.
At least 200 mutations have been identified in NOTCH3 and are located in N3-ECD. Those 
missense mutations create or destroy cysteine residues. As the name of disease indicates, 
they are inherited in the autosomal dominant pattern. NOTCH3 consists of 33 exons, but 73% 
of mutations are localized in exon 4, 8% in exon 3, 6% in exons 5 and 6 [99, 106, 107]. The 
first step of genetic screening is analyze of exon 4, if there are no mutations the analysis is 
extended to exons 2, 3, 5, 6, and 11. The last step may be the screening of all exons using next 
generation sequencing (NGS). Different NOTCH3 mutations were revealed among Asian of 
Caucasian populations [108, 109].
The CADASIL scale proposed by Pescini et al. [110] for selecting patients for genetic analysis 
is summarized in Table 1. A total score of ≥15 is an indication for genetic testing. The clinical 
course of CADASIL may vary between individuals with the same mutation in NOTCH3 gene. 
The heterogenic manifestation of clinical symptoms makes the CADASIL underdiagnosed 
CADASIL scale Points
Migraine
Migraine with aura
Stroke
Stroke onset ≤50 years
Psychiatric disturbances
Cognitive decline/dementia
Leukoencephalopathy
Leukoencephalopathy extended to temporal pole
Leukoencephalopathy extended to external capsule
Subcortical infarcts
Family history in at least one generation
Family history in at least two generations
1
3
1
2
1
3
3
1
5
2
1
2
Table 1. Scale used to select CADASIL patients for genetic screening of NOTCH3 mutations [110].
Migraine and Risk Factors of Vascular Diseases
http://dx.doi.org/10.5772/intechopen.72570
9
due to difficulties in distinguishing with, e.g., MA, familial hemiplegic migraine, or progres-
sive ataxia [107]. The NOTCH3 mutation analysis should be performed in cases with clinical 
features of CADASIL, even with the negative disease history.
There are two hypothesis explaining the role of NOTCH3 mutations in CADASIL pathomech-
anism. According to the first of them, the mutated NOTCH3 receptor gains new functions 
leading to the development of degenerative changes in blood vessels. The signaling pathway 
is unchanged, but the cerebral blood flow autoregulation is disturbed due to the decline of 
VSMC functions. The persistent stress conditions lead to VSMC remodeling, reduction of 
cerebral vasoreactivity, the decrease in blood flow in white matter, and in consequence to 
chronic ischemia. The second hypothesis assumes proteinopathy as a result of N3-ECD and 
granular osmiophilic material (GOM) deposition in walls of blood vessels. The GOM is also 
presented in skin biopsy. Abnormal folded NOTCH3 protein tends to create aggregates and 
is not removed because of dysfunction of the ubiquitin-proteasome system. The deposition 
begins in 20-year-old CADASIL patients, while the changes in MRI are visible in 30-year-old 
patients. Interestingly, almost all CADASIL patients aged 35 with NOTCH3 mutations have 
changes in MRI, e.g., white matter hyperintensities (WMH), lacunar infarcts or microbleeds. 
WMH lesions in T2 and FLAIR sequences may be presented even 15 years before stroke [111–
113]. Four case-studies indicated that the brain MRI may be unremarkable [114].
4. Summary
Migraine is a multifactorial disease with both genetic and environmental background. 
Polymorphisms and mutations in numerous genes, e.g., ACE, NOTCH3, MTHFR, MTR, 
MTRR, MTHFD1, CBS, and eNOS are the genetic factors involved in its pathomechanism. 
Changes in biochemical parameters, such as Hcy and ADMA leading to CVD, stroke and 
Figure 2. Association between migraine and cardiovascular diseases, stroke and genetic, or biochemical risk factors. ACE: 
angiotensin I-converting enzyme; CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; MTHFR: methylenetetrahydrofolate reductase; MTR: 5-methyltetrahydrofolate-homocysteine 
methyltransferase; MTRR-5: methyltetrahydrofolate-homocysteine methyltransferase reductase; CBS: cystathionine 
β-synthase; eNOS: endothelial NO synthase; Hcy: homocysteine; ADMA: asymmetric dimethylarginine.
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migraine may be a result of lifestyle. Migraine alone can also lead to CVD and stroke. It 
seems that better knowledge of the migraine pathomechanism may lead to early diagnosis of 
migraine and the introduction of more effective pharmacotherapy and, in consequence, to the 
prevention of common vascular disease (Figure 2).
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